Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 75 mg - tablet, film coated - excipient ingredients: lactose monohydrate; betadex; croscarmellose sodium; magnesium stearate; lactose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; macrogol 4000; polyvinyl alcohol; ferrosoferric oxide - briviact tablets are indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose; magnesium stearate; croscarmellose sodium; betadex; lactose monohydrate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - briviact tablets are indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 25 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; lactose monohydrate; betadex; magnesium stearate; lactose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - briviact tablets are indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 10 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose; lactose monohydrate; croscarmellose sodium; betadex; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - briviact tablets are indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 100 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; betadex; lactose monohydrate; magnesium stearate; lactose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - briviact tablets are indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - moxonidine, quantity: 200 microgram - tablet, film coated - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; povidone; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - moxonidine gh is indicated for the treatment of hypertension

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - moxonidine, quantity: 400 microgram - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; lactose monohydrate; povidone; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - moxonidine gh is indicated for the treatment of hypertension

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - moxonidine, quantity: 200 microgram - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; crospovidone; povidone; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - apo-moxonidine (moxonidine tablets) is indicated for the treatment of hypertension.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - moxonidine, quantity: 400 microgram - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; magnesium stearate; crospovidone; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - apo-moxonidine (moxonidine tablets) is indicated for the treatment of hypertension.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - cabotegravir, quantity: 30 mg (equivalent: cabotegravir sodium, qty mg) - tablet, film coated - excipient ingredients: titanium dioxide; magnesium stearate; hypromellose; lactose monohydrate; microcrystalline cellulose; sodium starch glycollate type a; macrogol 3350 - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna <50 copies/ml) and have no known or suspected resistance to either cabotegravir or rilpivirine (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties, clinical trials) for: ? oral lead in to assess tolerability of cabotegravir prior to administration of cabotegravir prolonged-release suspension for injection plus rilpivirine prolonged-release suspension for injection. ? oral therapy for adults who will miss planned dosing with cabotegravir prolonged-release suspension for injection.